ArticleDrug delivery and translational research2025
Traversing the Valley of Death for nanotechnology-based natural products: strategies and insights from pharmaceutical stakeholders.
Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Multi-Target Antitumor Effects of Natural Products and Approved Drug Repurposing in Non-Small Cell Lung Cancer: Advances in Mechanisms, Combination Regimens, Delivery System Optimization, and Clinical Challenges.International journal of molecular sciences · 2026Review
- Advances in Near-Infrared BODIPY Photosensitizers: Design Strategies and Applications in Photodynamic and Photothermal Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Intelligent information management enables quality-by-design in pharmaceutical production.Scientific reports · 2025Article
- Natural Products with Pharmaceutical Activities.Molecules (Basel, Switzerland) · 2025Article
- Nanotechnology Driven Innovations in Modern Pharmaceutics: Therapeutics, Imaging, and Regeneration.Nanomaterials (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology-based natural products hold significant therapeutic promise by improving the bioavailability and efficacy of natural products. However, their translation from laboratory to clinic remains hindered by a complex interplay of strategic misalignment, regulatory complexity, and organisational hurdles, often leading to failure in the so-called “Valley of Death”. To understand the drivers of successful translation and commercialisation, this study engaged 16 pharmaceutical stakeholders through semi-structured, in-depth interviews. Thematic analysis revealed three critical enablers. First, product-market fit requires early integration of market analysis and need-driven innovation to ensure alignment with unmet medical needs and commercial viability. Moreover, effective articulation of value propositions is essential to translate technical performance into perceived value for both investors and end-users. Second, product differentiation and positioning are essential to communicate competitive advantage in a crowded and cost-sensitive market. Strategic use of comparators, value metrics, and strategic messaging are critical to demonstrate tangible benefits over existing formulations, while avoiding unnecessary complexity to preserve affordability. Third, cross-sector and horizontal collaborative networks across academia, industry, regulators, manufacturers, and peer companies play a vital role in overcoming translational challenges by fostering regulatory preparedness and pooling complementary expertise and resources. Building on these findings, we propose the NATURAL framework as a translational planning tool to support early decision-making by helping innovators anticipate key barriers, align strategies, and improve the likelihood of clinical translation. Altogether, this study offers actionable insights and a structured planning tool to de-risk and accelerate the translation of nano-based natural products from bench to market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.